technologynetworks.com
Gene Variants That Cause Crohn's Disease Identified
The study pinpoints a genetic cause (BIRC3 variants) that disrupts a TNF/RIPK1 immune pathway linked to Crohn’s disease, suggesting a targetable mechanism. That could help doctors match patients to treatments and guide development of more precise therapies.
Patients with Crohn’s disease (including those with early-onset or familial disease), caregivers, pediatric and adult IBD clinicians, geneticists, and researchers working on IBD genetics, immune pathways, or targeted therapies.
What To Know
Researchers at SickKids report identifying variants in the BIRC3 gene that disrupt RIPK1/TNF signaling and were found in 14 Crohn’s patients from 10 families. The team used genetics, RNA sequencing, proteomics and animal models (mouse and zebrafish) and published the findings in Gastroenterology.
They suggest the pathway may be druggable and could help predict anti-TNF response; a RIPK1 inhibitor is already in clinical trials. What this means: this study identifies a new monogenic cause of Crohn’s linked to BIRC3 and maps how those variants cause inflammation through a RIPK1-related TNF pathway.
The authors propose that the pathway could be targeted for precision treatments and that some adult-onset or familial Crohn’s cases might have similar single-gene drivers.
Practical takeaway: this is a genetics-driven discovery that may lead to more targeted options and better matching of therapies in the future, but it describes a rare genetic cause and research steps (models, pathway mapping) rather than an immediate change in clinical care.
If you’re interested in more detail: the published paper in Gastroenterology is the primary source for methods, patient numbers, and specific data supporting these conclusions.
The report is based on a published Gastroenterology study combining human genetics and lab models; the identified cause appears rare but may illuminate a common pathway. Findings point toward future precision applications, not immediate clinical practice changes. A RIPK1 inhibitor is in trials, but patient use would depend on further clinical evidence and approvals.
